Lilly Announces Agreement to Acquire Disarm Therapeutics

Acquisition expands Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's promising preclinical SARM1 programs for axonal degeneration INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced a definitive